company background image
APRE logo

Aprea Therapeutics NasdaqCM:APRE Stock Report

Last Price

US$3.05

Market Cap

US$16.6m

7D

-6.4%

1Y

-18.4%

Updated

23 Dec, 2024

Data

Company Financials +

Aprea Therapeutics, Inc.

NasdaqCM:APRE Stock Report

Market Cap: US$16.6m

APRE Stock Overview

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. More details

APRE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Aprea Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aprea Therapeutics
Historical stock prices
Current Share PriceUS$3.05
52 Week HighUS$8.85
52 Week LowUS$2.15
Beta1.54
1 Month Change5.90%
3 Month Change2.35%
1 Year Change-18.45%
3 Year Changen/a
5 Year Changen/a
Change since IPO-77.47%

Recent News & Updates

Recent updates

Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?

Aug 06
Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Aprea Therapeutics' (NASDAQ:APRE) Cash Burn Rate

Jan 10
We're Keeping An Eye On Aprea Therapeutics' (NASDAQ:APRE) Cash Burn Rate

Shareholder Returns

APREUS BiotechsUS Market
7D-6.4%-3.8%-2.7%
1Y-18.4%-2.6%23.4%

Return vs Industry: APRE underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: APRE underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is APRE's price volatile compared to industry and market?
APRE volatility
APRE Average Weekly Movement13.6%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: APRE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: APRE's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a7Oren Giladwww.aprea.com

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors.

Aprea Therapeutics, Inc. Fundamentals Summary

How do Aprea Therapeutics's earnings and revenue compare to its market cap?
APRE fundamental statistics
Market capUS$16.58m
Earnings (TTM)-US$13.51m
Revenue (TTM)US$1.31m

12.6x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APRE income statement (TTM)
RevenueUS$1.31m
Cost of RevenueUS$9.05m
Gross Profit-US$7.74m
Other ExpensesUS$5.77m
Earnings-US$13.51m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.49
Gross Margin-590.41%
Net Profit Margin-1,030.42%
Debt/Equity Ratio0%

How did APRE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aprea Therapeutics, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Joseph PantginisH.C. Wainwright & Co.
Jason McCarthyMaxim Group